RAVEN MILLER: Open Payments
NPI 1578190443 · PETAL, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,847 in 129 payments from 19 companies in 2025. Trend: 2023 $1,006 · 2024 $1,234 · 2025 $1,847
Food & beverage: $1,736Education: $111
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 29 | $302 |
| Regeneron Healthcare Solutions, Inc. | 12 | $290 |
| Janssen Biotech, Inc. | 13 | $217 |
| GENZYME CORPORATION | 10 | $212 |
| Galderma Laboratories, L.P. | 20 | $182 |
| Novartis Pharmaceuticals Corporation | 18 | $154 |
| MAYNE PHARMA COMMERCIAL LLC | 9 | $86 |
| Amgen Inc. | 4 | $70 |
| SANOFI-AVENTIS U.S. LLC | 1 | $56 |
| PFIZER INC. | 2 | $54 |
Products named: DUPIXENT, TREMFYA, NEMLUVIO, SKYRIZI, COSENTYX, RINVOQ, OTEZLA, CIBINQO.
Industry payments across MS — which companies pay providers there.
